Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Lumosa Therapeutics Co Ltd (6535) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8021)・商品コード:DATA904C8021
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:19
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Lumosa Therapeutics Co Ltd (Lumosa Therapeutics) is a developer of drugs for the treatment of neurological and inflammatory diseases. The company’s pipeline products include LT-1001, an analgesic injection for severe pain relief; and LT-3001, a novel small molecule for acute ischemic stroke. Its activities comprise chemical development, translational research, preclinical, intellectual property, regulatory affairs, clinical development, project management and business development. Lumosa Therapeutics’s translational research services include disease model development, in vitro biassay development, acute toxicity pilot evaluation, bioanalytical method development, product stability analysis, compound purity analysis, and others. The company partners with biotech and pharmaceutical companies for product licensing, development and commercialization. Lumosa Therapeutics is headquartered in Taipei, Taiwan.

Lumosa Therapeutics Co Ltd (6535) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Lumosa Therapeutics Enters into Agreement with Camargo Pharma 10
Licensing Agreements 11
InteRx Biomedical Enters into Licensing Agreement with Lumosa Therapeutics 11
Equity Offering 12
Lumosa Therapeutics to Raise USD14.5 Million in Public Offering of Shares 12
Shundu Therapeutics Raises Funds through Private Placement 13
Lumosa Therapeutics Co Ltd – Key Competitors 14
Lumosa Therapeutics Co Ltd – Key Employees 15
Lumosa Therapeutics Co Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
03/14/2017: Lumosa’s LT1001 Approved in Taiwan 17
Product Approvals 18
Aug 28, 2017: Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain in the US 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumosa Therapeutics Enters into Agreement with Camargo Pharma 10
InteRx Biomedical Enters into Licensing Agreement with Lumosa Therapeutics 11
Lumosa Therapeutics to Raise USD14.5 Million in Public Offering of Shares 12
Shundu Therapeutics Raises Funds through Private Placement 13
Lumosa Therapeutics Co Ltd, Key Competitors 14
Lumosa Therapeutics Co Ltd, Key Employees 15

List of Figures
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8021)販売に関する免責事項を必ずご確認ください。
★調査レポート[Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆